LONDON, United Kingdom & BOSTON, Massachusetts, USA – June 8, 2026
GSK has announced a definitive agreement to acquire Nuvalent, Inc. in a transaction valued at approximately $10.6 billion, significantly strengthening its oncology portfolio and accelerating its strategic expansion into precision lung cancer therapies. The acquisition brings three promising targeted cancer assets into GSK’s pipeline, including zidesamtinib (NVL-520) and neladalkib (NVL-655), two late-stage, potential best-in-class therapies for non-small cell lung cancer (NSCLC) currently under review by the U.S. Food and Drug Administration (FDA). The transaction represents one of the largest oncology acquisitions of 2026 and reflects GSK’s commitment to acquiring innovative therapies that address significant efficacy and tolerability limitations associated with current standards of care. Company executives believe the acquisition will provide immediate growth opportunities, expand GSK’s presence in precision oncology, and establish a strong platform for future lung cancer innovation. With both lead assets potentially launching in 2026 pending regulatory approvals, the acquisition positions GSK to become a more significant competitor in one of the fastest-growing segments of cancer treatment.
Late-Stage Oncology Assets Strengthen GSK’s Pipeline
At the center of the acquisition are zidesamtinib and neladalkib, two highly selective next-generation kinase inhibitors designed for patients with genetically defined forms of NSCLC. Zidesamtinib targets ROS1-positive lung cancer, while neladalkib is being developed for ALK-positive NSCLC, both representing important molecular subtypes with significant unmet clinical needs. The therapies have received FDA Breakthrough Therapy and Orphan Drug Designations and are currently under regulatory review, with FDA decision dates expected in September and November 2026, respectively. Clinical data presented at major international oncology conferences have demonstrated encouraging efficacy, durable treatment responses, improved tolerability profiles, and enhanced penetration into the central nervous system, a critical factor for patients at risk of brain metastases.
These differentiated characteristics position both candidates as potential best-in-class therapies capable of addressing limitations associated with existing targeted treatments. If approved, GSK expects the products to have multi-blockbuster commercial potential and contribute significantly to long-term revenue growth.
Expanding Precision Medicine in Lung Cancer
Advertisement
Beyond the two lead assets, the acquisition also includes NVL-330, an investigational HER2-targeted therapy currently in Phase I clinical development for HER2-altered NSCLC, along with several earlier-stage research programs. Together, these assets provide GSK with a comprehensive precision oncology platform focused on genetically driven lung cancers. Non-small cell lung cancer remains the most common form of lung cancer globally and is increasingly being treated through biomarker-guided approaches that match therapies to specific molecular alterations. Nuvalent has built its pipeline around highly selective therapies designed to overcome resistance mechanisms, improve safety profiles, and deliver more durable clinical outcomes.
The company’s expertise in structure-based drug design and precision medicine complements GSK’s broader oncology strategy and strengthens its capabilities in developing targeted cancer treatments. Industry observers view the acquisition as a significant strategic move that enhances GSK’s competitive position within precision oncology while creating opportunities for future pipeline expansion.
Multi-Billion-Dollar Deal Supports Long-Term Growth Strategy
Under the terms of the agreement, GSK will acquire all outstanding shares of Nuvalent for $124 per share in cash, representing a substantial premium to the company’s recent trading price. The total equity value of the transaction is estimated at $10.6 billion, with a net investment of approximately $9.4 billion after accounting for acquired cash balances. GSK expects the acquisition to contribute to revenue growth beginning in 2027 and support its long-term ambition of achieving more than £40 billion in annual sales by 2031.
Company leadership believes the transaction will become accretive to core operating profit in 2027 and contribute positively to earnings per share by 2029. As competition intensifies in the oncology sector, acquisitions of late-stage targeted therapies have become a critical strategy for expanding portfolios and maintaining growth. The Nuvalent acquisition not only strengthens GSK’s lung cancer franchise but also reinforces its commitment to delivering innovative, precision-based treatments for patients facing serious and life-threatening cancers worldwide.
Source: GSK, Nuvalent press release
